SPRB
- Spruce Biosciences, Inc.
()
Overview
Company Summary
Spruce Biosciences, Inc. is a pharmaceutical company that focuses on developing and commercializing novel therapies for rare endocrine disorders. They aim to address unmet medical needs in diseases where there are limited or no treatment options currently available.
Their main therapeutic area of focus is congenital adrenal hyperplasia (CAH), a genetic disorder that affects the adrenal glands, leading to the overproduction of certain hormones. CAH can cause a range of symptoms and complications throughout a patient's life.
Spruce Biosciences is dedicated to developing innovative treatments for CAH and improving the well-being and quality of life for patients. Their lead product candidate, tildacerfont, is an investigational therapy currently undergoing clinical trials. Tildacerfont aims to normalize hormone levels in CAH patients by inhibiting androgen excess, reducing disease burden and potentially preventing long-term complications associated with the condition.
In addition to their CAH program, Spruce Biosciences is also exploring the potential applications of tildacerfont in other rare endocrine disorders. They are committed to advancing the understanding and treatment of these conditions through research and development efforts.
Overall, Spruce Biosciences is dedicated to making a meaningful impact in the lives of patients with rare endocrine disorders, providing them with innovative therapeutic options and improving their health outcomes.